Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: firstname.lastname@example.org
The iPhone maker racked up another quarter of so-so growth – and astonishing cash flow. CEO Tim Cook has paid out more than $40 bln over 12 months but added nearly $20 bln to the kitty. The lower share count may fuel a stock run-up if Apple soon unveils another must-have device.
The $57 bln data storage company is in the crosshairs of aggressive hedge fund Elliott Management. EMC says its “federation” enables subsidiaries including VMware to cooperate and create value. Growing competition between the parts and a valuation discount suggest otherwise.
The U.S. pharmaceutical group’s fifth offer, at $55 bln, finally persuaded its UK rival to sell. A 53 pct premium is a hefty price to pay given the modest synergies and potentially ephemeral tax arbitrage savings. Shire’s rare-disease drugs, however, should have lasting benefits.
- Microsoft carefully dismantles Ballmer legacy
- Murdoch may be heading for Pyrrhic Time Warner win
- China's "De-IOE" campaign takes a bite out of tech
- Battery wager should give chemicals maker a jolt
- Mylan sets itself for M&A repeat prescription
- Allergan may give investors yet another option
- Shire can get more from AbbVie